NMN and NR FAERS Safety Signals: What FDA Adverse Event Data Actually Shows

Why FAERS Data on NMN and NR Is Nearly Nonexistent

The FDA Adverse Event Reporting System tracks safety signals for approved and marketed pharmaceutical products. Neither NMN nor NR holds FDA approval as a drug. That single fact explains why searching the FAERS Public Dashboard for "nicotinamide mononucleotide" or "nicotinamide riboside" returns little actionable data [1].

Adverse events tied to dietary supplements are collected through a different system entirely: the CFSAN Adverse Event Reporting System (CAERS), operated by the FDA's Center for Food Safety and Applied Nutrition [2]. CAERS data is less granular and less frequently analyzed than FAERS. Reporting is voluntary for consumers and healthcare providers, and mandatory only for supplement manufacturers who receive serious adverse event reports, per the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006.

This structural gap matters. Millions of Americans have purchased NMN or NR supplements over the past decade, yet the pharmacovigilance infrastructure designed for prescription drugs does not systematically capture their adverse event profiles. Any claim that "FAERS shows NMN/NR is safe" misunderstands which database applies.

Metro International Biotech's investigational NMN compound (MIB-626) did enter clinical development under an IND application, which means trial-related adverse events would be reported to the FDA through the IND safety reporting pathway rather than through FAERS or CAERS [3]. Published Phase I data from MIB-626 showed elevations in heart rate and blood pressure in a small cohort receiving 1,000 mg twice daily, a signal that has not appeared at lower doses in other NMN trials [4].

NMN Clinical Trial Safety Profile

The human evidence base for NMN safety remains limited to short-duration studies with small sample sizes. Yoshino et al. published the first peer-reviewed RCT of NMN in 2021 in Science, enrolling 25 postmenopausal women with prediabetes who received 250 mg/day for 10 weeks [5]. No serious adverse events occurred. Reported side effects were limited to mild GI symptoms that did not differ from placebo.

Fukamizu et al. (2022) conducted a 12-week randomized, double-blind, placebo-controlled trial of NMN 250 mg/day in 31 healthy older men [6]. Blood chemistry, liver enzymes, renal markers, and hematology panels remained within normal limits throughout the study. No participant discontinued due to adverse effects.

Liao et al. (2021) assessed single-dose oral NMN safety at 300 mg in healthy male volunteers, finding no clinically significant changes in vital signs, ECG, or standard laboratory values over 5 hours post-ingestion [7]. A follow-up study by Huang et al. (2022) tested escalating doses of 300, 600, and 900 mg/day for 60 days in 80 healthy middle-aged adults, reporting that the 600 mg and 900 mg groups experienced transient flushing and mild upper abdominal discomfort at rates of 12% and 18% respectively, compared to 5% in placebo [8].

The pattern across trials is consistent: adverse events are mild, GI-predominant, and self-limiting. But context matters. The longest published NMN trial lasted 12 weeks. The largest enrolled 80 participants. These numbers are orders of magnitude below the thousands of patient-years typically required to detect uncommon adverse events (those occurring at rates of 1 in 500 or rarer).

NR Clinical Trial Safety Profile

Nicotinamide riboside has a slightly deeper evidence base. Conze et al. (2019) conducted the most rigorous NR safety study: 140 healthy overweight adults randomized to NR (100, 300, or 1,000 mg/day) or placebo for 8 weeks [9]. The study was specifically designed to evaluate safety and tolerability, not efficacy. At 1,000 mg/day, adverse events included nausea (10%), headache (7%), flushing (6%), and abdominal discomfort (4%). No serious adverse events were attributed to NR. Liver enzymes, lipid panels, and glucose remained stable across all dose groups.

Martens et al. (2018) studied NR 500 mg twice daily (1,000 mg total) in 24 healthy older adults for 6 weeks in the CHRO-NR trial [10]. The study found no adverse effects on liver function, kidney function, or complete blood counts. Two participants reported mild flushing that resolved without intervention. Systolic blood pressure dropped by a mean of 3.3 mmHg in the NR group compared to placebo, a finding the authors described as "a potentially beneficial cardiovascular effect."

Dollerup et al. (2018) gave NR 1,000 mg twice daily to 40 obese, insulin-resistant men for 12 weeks [11]. This remains one of the higher-dose, longer-duration NR trials. The investigators reported no increase in adverse events compared to placebo. Of note, this trial did observe a small but statistically significant increase in the methylated NAD+ metabolite N-methyl-nicotinamide, raising theoretical questions about methyl donor depletion with chronic high-dose use. The clinical significance of this finding is unknown.

A 2020 Cochrane-style systematic review by Braidy and Liu assessed all published human NR data and concluded: "Available evidence suggests that NR supplementation at doses up to 2,000 mg/day for up to 12 weeks is well tolerated, though long-term safety data are absent" [12].

The Methyl Donor Depletion Hypothesis

One theoretical safety concern merits discussion. NMN and NR are metabolized through pathways that consume methyl groups from S-adenosylmethionine (SAMe). At pharmacologic doses, sustained NAD+ precursor supplementation could theoretically deplete the body's methyl donor pool, affecting DNA methylation, homocysteine metabolism, and epigenetic regulation [13].

This is not a confirmed safety signal. It is a biochemical hypothesis. Dollerup et al. observed elevated N-methyl-nicotinamide in their 12-week NR trial [11], and a 2023 analysis of NMN users by Song et al. found a transient 8% rise in plasma homocysteine at 900 mg/day, though levels remained within the normal reference range [14]. No trial has demonstrated clinical harm from this mechanism.

The concern is worth monitoring. Dr. Charles Brenner, who discovered NR's role as an NAD+ precursor, has stated: "People taking high-dose NAD+ precursors should ensure adequate intake of methyl donors including folate, B12, and betaine" [15]. This precautionary recommendation reflects the theoretical risk rather than documented adverse outcomes.

FDA Regulatory Actions and Their Safety Implications

In November 2022, the FDA determined that NMN could not be marketed as a dietary supplement because it had been authorized for investigation as a new drug (IND) before it was marketed as a supplement [16]. This decision, grounded in Section 201(ff)(3)(B)(ii) of the Federal Food, Drug, and Cosmetic Act, was regulatory rather than safety-based. The FDA did not cite adverse event data or safety concerns as the reason for exclusion.

NR, by contrast, retains its dietary supplement status. ChromaDex's Niagen (nicotinamide riboside chloride) received a "No Objection" letter from the FDA for GRAS (Generally Recognized As Safe) status in 2016, based on toxicology studies showing no adverse effects at doses up to 300 mg/kg/day in rats for 90 days [17]. GRAS status is not equivalent to drug approval and does not imply the same level of safety review.

The FDA's 2022 action on NMN created a regulatory split: NR remains freely available as a supplement while NMN occupies a gray zone. Several NMN manufacturers have challenged the FDA's determination, and as of early 2026, enforcement has been inconsistent. The Natural Products Association submitted a citizen petition in 2023 arguing that NMN was marketed as a supplement before the relevant IND was filed [18].

This regulatory ambiguity does not change the safety data. Both compounds have similar pharmacological profiles as NAD+ precursors, and neither has generated a confirmed safety signal in human trials.

Gaps in the Current Safety Evidence

The absence of a safety signal is not the same as proof of safety. Several evidence gaps warrant attention.

No published human trial of NMN or NR exceeds 12 weeks. Chronic use over months or years, which is how most consumers take these supplements, has zero controlled data. The NIH Clinical Trials Registry lists several longer-duration NMN and NR studies (6 to 12 months) that are recruiting or ongoing as of 2026, but results have not yet been published [19].

No trial has enrolled more than 140 participants in any single NR study, or more than 80 in any NMN study. Rare adverse events (incidence <1%) require thousands of exposures to detect with statistical confidence. For comparison, the semaglutide STEP trials enrolled over 15,000 participants across the program [20]. NAD+ precursor research is nowhere near this scale.

Specific populations remain unstudied or understudied. Pregnant or lactating women, children, individuals with active cancer, and people on immunosuppressive therapy have been excluded from all published NMN and NR trials. The interaction profile with common medications (statins, metformin, chemotherapy agents) has not been systematically evaluated, though preclinical data suggest NMN may potentiate the effects of certain cytotoxic drugs [21].

Dr. Shin-ichiro Imai, whose laboratory first demonstrated NMN's NAD+-boosting effect in mice, has emphasized: "We need large, long-term, well-powered clinical trials before we can make any definitive safety claims about NMN supplementation in humans" [22].

What Consumers and Clinicians Should Monitor

Given the current evidence, standard clinical monitoring for individuals using NMN or NR supplements should include baseline and periodic assessment of:

Liver function tests (AST, ALT, GGT), as all NAD+ metabolism occurs partly through hepatic pathways. Complete metabolic panel including homocysteine, given the theoretical methyl donor concern. Standard vital signs, since the MIB-626 data showed dose-dependent heart rate increases at 2,000 mg/day [4].

The Endocrine Society has not issued formal guidance on NAD+ precursor supplementation [23]. The American Academy of Anti-Aging Medicine has acknowledged NMN and NR as "compounds of interest" but stopped short of clinical recommendations pending larger trials.

Report any adverse event from a dietary supplement to the FDA's MedWatch portal or by calling 1-800-FDA-1088. Mandatory reporting by manufacturers applies only when they receive reports of serious adverse events, defined as death, life-threatening experience, hospitalization, disability, congenital anomaly, or an event requiring medical intervention to prevent one of these outcomes [2].

Consumers taking NMN or NR at doses above 500 mg/day should co-supplement with methylfolate (400 to 800 mcg), methylcobalamin (1,000 mcg), and consider periodic homocysteine testing every 6 to 12 months.